Bromantane dosage

Protocol

1. 1

   Measure the dose

   Typical Bromantane dose is 75 mg (Russian clinical range 50 to 100 mg daily, taken in the morning). Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer daily, morning. Half-life of 11 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   Russian protocols typically run 4 to 6 week blocks with 2 to 4 week washouts; long-term continuous use is undocumented

   Open tool →
4. 4

   Monitor for side effects

   Watch for: mild GI upset; headache; skin rash; occasional insomnia at higher doses. Stop or reduce dose if tolerability breaks down.

Why this dose

Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus.

The typical dose (75 mg) reflects Russian clinical range 50 to 100 mg daily, taken in the morning. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Bromantane is administered via the oral route. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 3 hours after administration. Peak effect lands near 1 weeks post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Terminal half-life around 11 hours; oral bioavailability around 40%

Cycling and tolerance

Russian protocols typically run 4 to 6 week blocks with 2 to 4 week washouts; long-term continuous use is undocumented

Effects to expect at typical dose

• Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
• Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
• Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
• Long half-life of around 11 hours supports once-daily morning dosing
• WADA-banned since 1996; relevant for tested athletes
• Western evidence base is thin; most published trials are Russian-language and not independently replicated

Side effects and interactions

Common side effects

• mild GI upset
• headache
• skin rash
• occasional insomnia at higher doses

Notable interactions

• MAOIs (major): theoretical additive dopaminergic and serotonergic activity
• levodopa and dopamine agonists (moderate): additive dopaminergic activity
• SSRIs and other serotonergic drugs (moderate): theoretical serotonergic additivity
• classical stimulants (moderate): theoretical additive activity, undocumented

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Bromantane profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Not scheduled in the US

Pregnancy

Not recommended

Legal status

Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK

Do not use if

• pregnancy
• lactation
• severe hepatic impairment
• severe renal impairment
• pediatric use

Related research